Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has recently published preclinical data in Cancer Cells, highlighting the potential of its fusion protein candidate, TNX-1700, to enhance immunotherapy in gastric cancer. The study, conducted in collaboration with Columbia University Medical School, demonstrated that the murine version of TNX-1700 (mTNX-1700) significantly increased survival rates and reduced metastases in mouse models of gastric cancer. This breakthrough suggests a new avenue for overcoming resistance to checkpoint inhibitors, a major challenge in cancer treatment.
The mechanism behind TNX-1700's efficacy involves the depletion of immunosuppressive neutrophils and the inhibition of cancer-driven granulopoiesis, processes that often undermine the effectiveness of anti-PD-1 immunotherapy. Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, emphasized the importance of these findings, stating they support the further development of TNX-1700 as a means to address checkpoint resistance in solid tumors, including gastric and colorectal cancers.
This development is particularly significant given the high mortality rates associated with gastric cancer and the limited success of current treatments in advanced stages. The ability of TNX-1700 to enhance the effectiveness of existing immunotherapies could lead to improved outcomes for patients, offering hope where options are currently limited. The human version of TNX-1700 is now in development, with the aim of bringing this promising treatment to clinical trials.
For more details on the study and its implications, visit https://ibn.fm/PPxKC.
